Newsletter | November 18, 2026

11.18.26 -- Which mRNA-LNP CQAs Deserve More Attention Today?

SPONSOR

Webinar: Understanding the Impact of IVT mRNA Impurities on Cellular Responses

Not all mRNA is created equal. But how much do impurities really impact therapeutic performance? Join Roche experts to explore how IVT mRNA impurities influence translation efficiency, reactogenicity, and cellular responses. Discover advanced analytical techniques for identifying critical impurities and learn how connecting purity profiles with biological functionality can strengthen quality control strategies for RNA-based therapeutics. Click here to learn more.

FEATURED EDITORIAL

The In Vivo CAR-T Playbook: Differentiating Your mRNA Candidates

Fortunately, as my conversation with ParcelBio CEO David Weinberg emphasized, there’s still a lot of room to grow in terms of what our RNA-based products can be and how they can perform. Here in part 2 of this two-part article, Weinberg walks me through how ParcelBio is approaching this market and helping define what a competitive mRNA product will look like in the in vivo CAR-T space.

Which mRNA-LNP Attributes Deserve Deeper Characterization Today?

This Advancing RNA Live panel, comprising Elaine Peters, Ilya Shestopalov, and Philippe Talaga, addresses which mRNA-LNP attributes could benefit the most from orthogonal extended characterization.

Can Engineering The Passenger Strand Improve siRNA Performance?

How can we make the passenger strand easier to reject while keeping the siRNA duplex sufficiently stable before it reaches the machinery that activates it?

INDUSTRY INSIGHTS

Connecting Oligonucleotide R&D With Early Clinical Scale Manufacturing

Watch the webinar for practical considerations that can support a smoother transition from oligonucleotide R&D to early clinical-scale manufacturing.

Can Targeted LNP Delivery Take In-Vivo CAR-T Therapy Beyond The Liver?

Achieving successful extrahepatic CAR T delivery with LNPs requires addressing the unique biological and technological barriers and designing targeting approaches that leverage innovative LNP design.

Screening T7 Polymerases To Optimize xRNA Yield And Quality

Discover how the evolution of T7 polymerase is optimizing in vitro transcription for RNA therapeutics. Learn to balance performance, cost, and supply to make smart choices for your xRNA manufacturing.

The Current And Future Value Of mRNA Vaccines And Therapeutics

Gain insight into how decades of research have propelled mRNA technology to the forefront of therapeutic development and learn how our expertise is advancing mRNA drug development.

Manufacturing Strategies For mRNA Vaccines And Therapeutics

mRNA has emerged as a promising modality offering a great deal of versatility for a wide range of therapeutics and vaccines with its use of non-viral delivery systems.

mRNA Research Services To Accelerate Your Project

Codon optimization accelerates early mRNA projects by balancing manufacturability, stability, and expression upfront, shaping research toward scalable, low-immunogenicity candidates.

Evaluating AG-Capped RNA Workflows For Yield, dsRNA And Translatability

A strong capping result can hide deeper problems: elevated dsRNA, inconsistent yield across templates and UTRs, high cap analog needs, or poor translatability.

SOLUTIONS

mRNA Raw Materials: Supporting Your Journey To Market

Move Beyond LAL

Integrated CRISPR For Comprehensive Genomic Medicine Workflows

Lipids Center Of Excellence